Reuters logo
EMA panel backs Novo Nordisk's hemophilia B drug
March 24, 2017 / 12:35 PM / 9 months ago

EMA panel backs Novo Nordisk's hemophilia B drug

(Reuters) - A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk’s hemophilia B drug.

Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen, Denmark February 1, 2017. Scanpix Denmark/Liselotte Sabroe via REUTERS

The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Refixia, intended for the treatment and prevention of bleeding in patients 12 years and above with hemophilia B. bit.ly/2n1edgs

Hemophilia B is caused by the deficiency of the factor IX gene that is instrumental in blood clotting.

The panel’s opinion will now be reviewed by the EMA.

The positive recommendation comes at a time when Novo Nordisk struggles with declining sales from its aging diabetes franchise.

Last month, the Danish group warned that sales and profits might actually slip in 2017, a remarkable change in fortune for a company that was previously renowned for its sector-beating growth.

Outside diabetes, Novo Nordisk already has a significant blood products business focused on hemophilia.

Reporting by Rahul B in Bengaluru; Editing by Anil D'Silva

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below